CIK 0001372514
- Non-accelerated filer
- Smaller reporting company
KIORA PHARMACEUTICALS INC
Sign in to watch- Tickers
- KPRX KPHMW
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 980443284
- Phone
- +1 858-224-9600
- Business address
- 169 SAXONY RD., SUITE 212, ENCINITAS, CA, 92024
- Former names
- EYEGATE PHARMACEUTICALS INC
Securities
- KPRX Common Stock Nasdaq
- KPHMW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 73 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-28 | MANZO MICHAEL P. Vice President of Engineering | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2018-02-28 | Wirostko Barbara Chief Medical Officer | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2018-02-28 | FROM STEPHEN President and CEO | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2017-12-29 | Romano Sarah Chief Financial Officer | Other acquisition | +11,863 | $1.01 | $12K | 44,363 |
| 2017-12-29 | Wirostko Barbara Chief Medical Officer | Other acquisition | +12,355 | $1.01 | $12K | 240,397 |
| 2017-12-29 | Mann Brenda VP of Research & Development | Other acquisition | +6,722 | $1.01 | $7K | 18,473 |
| 2017-12-29 | FROM STEPHEN President and CEO | Other acquisition | +12,355 | $1.01 | $12K | 284,820 |
| 2017-11-17 | Garanzini Michael Chief Commercial Officer | Grant or award | +15,000 | $1.07 | $16K | 15,000 |
| 2017-11-17 | Garanzini Michael Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2017-09-15 | Wirostko Barbara Chief Medical Officer | Grant or award | +9,000 | $1.20 | $11K | 228,042 |
| 2017-09-14 | Wirostko Barbara Chief Medical Officer | Grant or award | +1,200 | $1.22 | $1K | 219,042 |
| 2017-09-14 | Wirostko Barbara Chief Medical Officer | Grant or award | +9,000 | $1.23 | $11K | 50,700 |
| 2017-08-15 | Romano Sarah Interim CFO | Purchase | +10,000 | $1.00 | $10K | 32,500 |
| 2017-08-10 | FROM STEPHEN President and CEO | Purchase | +12,500 | $1.03 | $13K | 272,465 |
| 2017-06-21 | MANZO MICHAEL P. Vice President of Engineering | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2017-06-21 | Romano Sarah Interim CFO | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2017-06-21 | Mann Brenda VP of Research & Development | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-21 | Wirostko Barbara Chief Medical Officer | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2017-06-21 | FROM STEPHEN President and CEO | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2017-06-21 | HANCOCK THOMAS Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 |
Page 22 of 24 · 468 trades